NCI COMPASS

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Abstract

The Molecular Diagnostics Section is currently the only CLIA and College of American Pathology approved clinical laboratory within the NCI certified for performing molecular oncology testing on pathology materials from NIH patients. The newly established COMPASS program is to expand next-generation sequencing to support clinical and research in CCR. In FY21, while the laboratory is continuing to utilize Ion Torrent NGS system to run the Primary Brain Tumor panel (PBTP) for some patients in NOB's Natural History Study we started to face out this old assay along with Oncomine assay. In FY21 (July 2020 - June 2021), the NGS lab run 1017 TSO500 tests. These results have provided support of precision pathological diagnosis and precision oncology for 79 clinical protocols from NCI and 1 protocol from NIDDK including CCR Rare Tumor, Liver and Prostate Cancer Moonshot projects. We are also screening the targets in patients from CCR intramural clinics for NCI-MATCH. In this year, the COMPASS program completed clinical whole exome sequencing assay development and validation. The test was launched in June 2021 on CRIS and is available to CCR clinical communities now. The COMPASS program provided the great opportunities of training or continuing education for both pathology and oncology teams especially next generation of pathologists and physician scientists by running weekly NGS technical review conference, weekly molecular pathology/neuro-oncology conference, and weekly molecular pathology/pediatric oncology conference to discuss molecular finding, treatment, and beyond pedicular patient or mutation.